Using 454 reads, researchers at Brigham and Women's Hospital sequenced tumors from four patients with mesothelioma, reports the Wall Street Journal. The researchers found that each patient had four to six mutated genes in their tumor cells compared with their healthy cells, but the patients each had different sets of mutations -- leading to speculation about drug selection. "What we need to do is pair up the right patient with the right drug," says David Sugarbaker, the lead author of the PNAS study.
Matchmaking Service Needed for Tumors and Treatments
Feb 26, 2008